PAT Guidance Will Draw From Existing Guidances On Electronic Records
Executive Summary
FDA plans to draw from existing guidances issued by the agency's device center to clarify 21 CFR Part 11 electronic record/electronic signature requirements in its planned PAT guidance
You may also be interested in...
FDA process analytical technology guidance
FDA will publish draft guidance on process analytical technology in September. "I hope you'll all have a chance in September...to read our new guidance document that we'll be releasing on the use of process analytical technology in making possible innovations in drug manufacturing and quality assurance," FDA Commissioner McClellan tells PQRI workshop Aug. 5. The draft guidance is expected to draw from the agency's existing guidance on 21 CFR Part 11 electronic record/electronic signatures (1"The Pink Sheet" Oct. 28, 2002, p. 30)...
FDA process analytical technology guidance
FDA will publish draft guidance on process analytical technology in September. "I hope you'll all have a chance in September...to read our new guidance document that we'll be releasing on the use of process analytical technology in making possible innovations in drug manufacturing and quality assurance," FDA Commissioner McClellan tells PQRI workshop Aug. 5. The draft guidance is expected to draw from the agency's existing guidance on 21 CFR Part 11 electronic record/electronic signatures (1"The Pink Sheet" Oct. 28, 2002, p. 30)...
Electronic Records Enforcement Relaxed During Part 11 Review, FDA Says
FDA intends to relax enforcement of its Part 11 regulation on electronic records while it reexamines the rule's application, a draft guidance document states